TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00237393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Study: NCT03041428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraprotective ventilation
Description: Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
Study: NCT04004585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Up For Your Health
Description: The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting.
Study: NCT02108093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde autologous priming
Description: Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
Study: NCT04085055

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Solid pancreatic mass lesion biopsy
Description: The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Solid pancreatic mass lesion biopsy
Description: The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Solid pancreatic mass lesion biopsy
Description: The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Solid pancreatic mass lesion biopsy
Description: The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
Study: NCT04272385

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT03261492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Safety Attention Comparison
Description: The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
Study: NCT03533309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided surgical cutting guide
Description: comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional alveolar ridge splitting
Description: comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
Study: NCT01403857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain foods
Description: Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined grains
Description: Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
Study: NCT01461447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Ankara
Description: Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
Study: NCT00582010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: inhaled 80ppm for duration of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrogen gas
Description: inhaled
Study: NCT03417687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI
Description: Evaluation of pulmonary function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI
Description: Evaluation of pulmonary function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 133 Xe scintigraphy
Description: Evaluation of pulmonary function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 133 Xe scintigraphy
Description: Evaluation of pulmonary function
Study: NCT02879903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiological collect
Description: Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
Study: NCT02124772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
Study: NCT02879903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microbiological collect
Description: Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
Study: NCT01652547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide sub-cutaneous formulation
Description: Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide lon acting release formulation
Description: At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
Study: NCT02124772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was administered orally, twice daily. The daily dose was divided into two equal doses. It was available in capsules (50 mg and 75 mg), dispersible tablets (10 mg) and powder for oral suspension (10 mg/mL dose).
Study: NCT04589143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks
Study: NCT02138552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
Study: NCT03907943

Intervention type: PROCEDURE
Group type: OTHER
Intervention: carotid endarterectomy
Description: Surgical treatment of ICA stenosis.
Study: NCT03006952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: losartan arm took 100mg losartan daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: losartan arm took 100mg losartan daily for 12 weeks.
Study: NCT05536934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nω-hydroxy-nor-arginine
Study: NCT02925780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microabrasion
Description: The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months).
Study: NCT00819052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine XR
Description: Nevirapine XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine XR
Description: Nevirapine extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine IR
Description: Nevirapine Immediate Release
Study: NCT00531310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning, Busulfan and Fludarabine
Description: Busulfan and Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning, Busulfan and Fludarabine
Description: Busulfan and Fludarabine
Study: NCT03794856

Intervention type: OTHER
Intervention: Functional and Structural Magnetic Resonance Imaging (research grade)
Description: Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.

Intervention type: OTHER
Intervention: Functional and Structural Magnetic Resonance Imaging (research grade)
Description: Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.

Intervention type: OTHER
Intervention: Cognitive Function Testing (non-diagnostic)
Description: Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.

Intervention type: OTHER
Intervention: Cognitive Function Testing (non-diagnostic)
Description: Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.

Intervention type: OTHER
Intervention: Asthma and Psychological Questionnaires (non-diagnostic)
Description: Participants will fill out asthma and psychological questionnaires (non-diagnostic)

Intervention type: OTHER
Intervention: Asthma and Psychological Questionnaires (non-diagnostic)
Description: Participants will fill out asthma and psychological questionnaires (non-diagnostic)
Study: NCT04678193

Intervention type: DRUG
Intervention: Coromec Registry with ECL-19
Description: Glycocheck to assess Microvascular Score will be used on all patients. An algorithm-based identification of symptoms and objective evidence using care coordination and remote sensor driven technology
Study: NCT02397980

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: * What the dementia is~* How to deal with behavioral problems in patients with dementia~* How to manage caregiver's stress~* How to care dementic patients as well as caregivers themselves
Study: NCT04272385

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT04230902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microfragmented Adipose Tissue Transplant
Description: Autologous Microfragmented Adipose Tissue derived using Lipogems® Kit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: intra-articular knee injection of corticosteroid
Study: NCT01450683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
Study: NCT02348255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric Field Therapy
Description: Undergo NovoTTF-100A

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01559389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks
Study: NCT03022097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol Fixed-Dose Combination
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Inhaled Aclidinium bromide 400 μg, twice per day via Genuair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
Study: NCT02637531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
Study: NCT00003167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Description: Given intravesically
Study: NCT02636114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planing
Description: Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
Study: NCT02637531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
Study: NCT04589143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks
Study: NCT02522442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto BiLevel
Description: Auto Bilevel positive airway pressure with Flex